Immunomedics’ Epratuzumab Enters Phase III Trials For Lupus

The B-cell modulator is beginning pivotal trials in patients with moderately active systemic lupus erythematosus and in patients with severe SLE flares. Other investigational lupus therapies have been held up by Phase III failures.